These have confirmed the high mutation frequency of known drivers such as PTEN and TP53 in endometrioid and non‐endometrioid tumours respectively, and identified over 30 other significantly recurrently mutated genes (Gallo et al, 2012; Cancer Genome Atlas Research Network et al, 2013; Zhao et al, 2013; Martincorena et al, 2017; Bailey et al, 2018; Martínez‐Jiménez et al, 2020). This evidence concerns the gene TP53 and neoplasm.